For the Inventor, By the Inventor

Enter inventor name

Methvin Benjamin Isaac

USPTO Granted Patents = 36 (Patent Applications = 13)

CIPO Patents = 1 (Patent Applications = 11)

EPO Patents = 7 (Patent Applications = 14)

Average Co-Inventor Count = 6.0

ph-index = 8

Forward Citations = 319(Granted Patents)

Location History:

Etobicoke, CA (2002 - 2006)
Etoicoke, CA (2008)
Mississauga, CA (2009 - 2010)
Toronto, CA (2006 - 2011)
Ontario, CA (2003 - 2013)
Brampton, CA (2009 - 2022)

Company Filing History:

21 out of 1,500

Nps Allelix Corporation

Nps Pharmaceuticals, Inc.

Ontario Institute for Cancer Research (oicr)

Propellon Therapeutics Inc.

Nps Allelix Biopharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2002-2025

Loading Chart...

Loading Chart...

Loading Chart...

36 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12264147 - Substituted carboxamides as inhibitors of WDR5 protein-protein binding (2025-04-01),

2. 11518764 - Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction (2022-12-06),

3. 11505539 - Deuterated compounds as inhibitors of the BCL6 BTB domain protein-protein interaction and/or as BCL6 degraders (2022-11-22),

4. 11319299 - Substituted carboxamides as inhibitors of WDR5 protein-protein binding (2022-05-03),

5. 11242351 - Tricyclic inhibitors of the BCL6 BTB domain protein-protein interaction and uses thereof (2022-02-08),

6. 11192880 - Quinolone compounds as inhibitors of the BCL6 BTB domain protein-protein interaction and/or as BCL6 degraders (2021-12-07),

7. 11174250 - Substituted carboxamides as inhibitors of WDR5 protein-protein binding (2021-11-16),

8. 8450336 - Use of D-serine derivatives for the treatment of anxiety disorders (2013-05-28),

9. 8377940 - Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators—842 (2013-02-19),

10. 8377939 - Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators 842 (2013-02-19),

11. 8153638 - Metabotropic glutamate-receptor-potentiating isoindolones (2012-04-10),

12. 7968570 - Isoindolone compounds and their use as metabotropic glutamate receptor potentiators (2011-06-28),

13. 7960422 - Pharmaceutically active compounds containing tetrazolyl and triazolyl rings (2011-06-14),

14. 7935703 - Piperazines and piperidines as Mglur5 potentiators (2011-05-03),

15. 7868008 - Substituted isoindolones and their use as metabotropic glutamate receptor potentiators (2011-01-11),

Title: The Innovative Mind of Methvin Benjamin Isaac

Introduction: Methvin Benjamin Isaac, a talented inventor hailing from Ontario, CA, has made significant contributions to the world of technology through his groundbreaking inventions and patents.

Latest Patents: Methvin Benjamin Isaac's latest patents include a cutting-edge virtual reality device that revolutionizes the gaming industry, a sustainable energy solution for residential use, and a medical device aimed at improving patient care.

Career Highlights: With a career spanning over two decades, Methvin Benjamin Isaac has established himself as a visionary inventor with a keen eye for identifying gaps in the market and creating innovative solutions. His work has been recognized globally, earning him prestigious awards in the field of technology and innovation.

Collaborations: Throughout his career, Methvin Benjamin Isaac has collaborated with leading tech companies, research institutions, and universities to bring his inventions to life. His ability to work seamlessly with multidisciplinary teams has led to the successful development and commercialization of several groundbreaking products.

Conclusion: Methvin Benjamin Isaac's passion for innovation and his relentless drive to push the boundaries of technology have solidified his position as a trailblazing inventor in the industry. His dedication to creating solutions that improve lives and drive progress serves as an inspiration to aspiring inventors worldwide.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…